Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
作者信息
Zheng Kenneth I, Gao Feng, Wang Xiao-Bo, Sun Qing-Feng, Pan Ke-Hua, Wang Ting-Yao, Ma Hong-Lei, Chen Yong-Ping, Liu Wen-Yue, George Jacob, Zheng Ming-Hua
机构信息
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
出版信息
Metabolism. 2020 Jul;108:154244. doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.
Abstract
摘要
相似文献
1
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者感染 COVID-19 时病情更严重的风险因素。
Metabolism. 2020 Jul;108:154244. doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.
2
Commentary: Obesity: The "Achilles heel" for COVID-19?评论：肥胖：新冠病毒的“阿喀琉斯之踵”？
Metabolism. 2020 Jul;108:154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27.
3
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者中COVID-19病情更严重的危险因素
Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29.
4
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.新型冠状病毒肺炎患者的非酒精性脂肪性肝病：一项回顾性研究。
J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8.
5
Letter to the Editor: Importance of metabolic health in the era of COVID-19.致编辑的信：新冠疫情时代代谢健康的重要性。
Metabolism. 2020 Jul;108:154247. doi: 10.1016/j.metabol.2020.154247. Epub 2020 Apr 22.
6
Metabolic-associated fatty liver disease is associated with severity of COVID-19.代谢相关脂肪性肝病与 COVID-19 的严重程度相关。
Liver Int. 2020 Sep;40(9):2160-2163. doi: 10.1111/liv.14575. Epub 2020 Jul 5.
7
Obesity and impaired metabolic health in patients with COVID-19.COVID-19 患者的肥胖和代谢健康受损。
Nat Rev Endocrinol. 2020 Jul;16(7):341-342. doi: 10.1038/s41574-020-0364-6.
8
COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?新型冠状病毒肺炎与药物性肝损伤：是个大问题还是小问题？
Arch Toxicol. 2020 Apr;94(4):1367-1369. doi: 10.1007/s00204-020-02734-1. Epub 2020 Apr 8.
9
Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19.致编辑的信：肥胖低通气综合征与重症新型冠状病毒肺炎
Metabolism. 2020 Jul;108:154249. doi: 10.1016/j.metabol.2020.154249. Epub 2020 Apr 22.
10
Will the COVID-19 pandemic worsen the obesity epidemic?新冠疫情是否会加剧肥胖症流行？
Nat Rev Endocrinol. 2020 Sep;16(9):469-470. doi: 10.1038/s41574-020-0387-z.
引用本文的文献
1
SARS-CoV-2 mRNA vaccines confer protection in diet-induced obese mice despite altered immune cell profiles in the lung.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗尽管会改变肺部免疫细胞谱，但仍能在饮食诱导的肥胖小鼠中提供保护。
Sci Rep. 2025 Jul 26;15(1):27209. doi: 10.1038/s41598-025-12320-z.
2
Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.COVID-19 中的细胞因子风暴：探索 IL-6 信号和细胞因子-微生物组相互作用作为新兴治疗方法。
Int J Mol Sci. 2024 Oct 24;25(21):11411. doi: 10.3390/ijms252111411.
3
Prognostic Value of Computed Tomography-Measured Visceral Adipose Tissue in Patients with Pulmonary Infection Caused by Carbapenem-Resistant .计算机断层扫描测量的内脏脂肪组织在耐碳青霉烯类药物引起的肺部感染患者中的预后价值
Infect Drug Resist. 2024 Oct 29;17:4741-4752. doi: 10.2147/IDR.S479302. eCollection 2024.
4
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.代谢（功能障碍）相关脂肪性肝病指标及其对肝脏研究的贡献。
Hepatol Int. 2024 Dec;18(6):1740-1755. doi: 10.1007/s12072-024-10731-0. Epub 2024 Oct 16.
5
Impact of the Geriatric Nutritional Risk Index on In-hospital Thrombosis and Mortality in Patients Hospitalized with COVID-19.老年营养风险指数对COVID-19住院患者院内血栓形成和死亡率的影响
Intern Med. 2025 Feb 15;64(4):519-526. doi: 10.2169/internalmedicine.2977-23. Epub 2024 Jul 11.
6
Spectrum of COVID-19 induced liver injury: A review report.新型冠状病毒肺炎所致肝损伤的研究现状：一篇综述报告
World J Hepatol. 2024 Apr 27;16(4):517-536. doi: 10.4254/wjh.v16.i4.517.
7
Food science and COVID-19.食品科学与2019冠状病毒病
Food Sci Hum Wellness. 2021 Jan;10(1):1-5. doi: 10.1016/j.fshw.2020.08.005. Epub 2020 Sep 23.
8
Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States.代谢功能障碍相关脂肪性肝病对新冠病毒疾病住院治疗的影响：美国的一项倾向匹配分析
World J Virol. 2024 Mar 25;13(1):91149. doi: 10.5501/wjv.v13.i1.91149.
9
Impact Of body Mass Index on Cardiopulmonary Outcomes of COVID-19 Hospitalizations Complicated by Severe Sepsis.体重指数对合并严重脓毒症的COVID-19住院患者心肺结局的影响
Obes Pillars. 2024 Feb 14;10:100101. doi: 10.1016/j.obpill.2024.100101. eCollection 2024 Jun.
10
Semantic and Population Analysis of the Genetic Targets Related to COVID-19 and Its Association with Genes and Diseases.与 COVID-19 相关的遗传靶点的语义和人群分析及其与基因和疾病的关联。
Adv Exp Med Biol. 2023;1423:59-78. doi: 10.1007/978-3-031-31978-5_6.
本文引用的文献
1
Obesity Is a Risk Factor for Greater COVID-19 Severity.肥胖是新冠病毒疾病（COVID-19）病情加重的一个风险因素。
Diabetes Care. 2020 Jul;43(7):e72-e74. doi: 10.2337/dc20-0682. Epub 2020 May 14.
2
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
3
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.新型冠状病毒肺炎与肝功能障碍：当前见解及新出现的治疗策略
J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018. Epub 2020 Mar 30.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.瘦型非酒精性脂肪性肝病：一种由不同代谢适应塑造的独特实体。
Hepatology. 2020 Apr;71(4):1213-1227. doi: 10.1002/hep.30908. Epub 2020 Jan 24.
7
Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia.非酒精性脂肪性肝病与成人社区获得性肺炎患者 30 天全因死亡率的关系。
QJM. 2019 Feb 1;112(2):95-99. doi: 10.1093/qjmed/hcy227.
8
Nonalcoholic fatty liver disease is associated with decreased lung function.非酒精性脂肪性肝病与肺功能下降有关。
Liver Int. 2018 Nov;38(11):2091-2100. doi: 10.1111/liv.13860. Epub 2018 May 3.
9
Obesity and Overweight in Asian People.亚洲人群中的肥胖与超重
Circ J. 2016 Nov 25;80(12):2425-2426. doi: 10.1253/circj.CJ-16-1087. Epub 2016 Nov 8.
10
The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease.肥胖相关非酒精性脂肪性肝病发生发展过程中缺氧与天然免疫的相互作用
Biomed Res Int. 2015;2015:319745. doi: 10.1155/2015/319745. Epub 2015 Sep 28.
Zotero 插件